Propel Bio Management LLC Sells 168,191 Shares of Zevra Therapeutics, Inc. $ZVRA

Propel Bio Management LLC lowered its stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 72.5% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 63,683 shares of the company’s stock after selling 168,191 shares during the quarter. Zevra Therapeutics makes up approximately 0.5% of Propel Bio Management LLC’s portfolio, making the stock its 19th largest holding. Propel Bio Management LLC’s holdings in Zevra Therapeutics were worth $571,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the stock. Marshall Wace LLP purchased a new stake in Zevra Therapeutics during the third quarter valued at about $8,676,000. Rubric Capital Management LP lifted its holdings in Zevra Therapeutics by 60.8% during the second quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company’s stock valued at $17,253,000 after purchasing an additional 740,584 shares during the last quarter. Royce & Associates LP purchased a new stake in Zevra Therapeutics during the third quarter valued at about $6,574,000. Adage Capital Partners GP L.L.C. lifted its holdings in Zevra Therapeutics by 15.2% during the second quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company’s stock valued at $36,720,000 after purchasing an additional 550,000 shares during the last quarter. Finally, Nantahala Capital Management LLC lifted its holdings in Zevra Therapeutics by 34.0% during the third quarter. Nantahala Capital Management LLC now owns 1,971,936 shares of the company’s stock valued at $18,753,000 after purchasing an additional 500,000 shares during the last quarter. Institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Trading Down 5.0%

ZVRA stock opened at $10.61 on Friday. The company’s 50 day moving average is $10.32 and its 200 day moving average is $9.37. The stock has a market cap of $627.26 million, a price-to-earnings ratio of 5.33 and a beta of 0.91. Zevra Therapeutics, Inc. has a 1-year low of $7.16 and a 1-year high of $13.16.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.18 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.12. The firm had revenue of $36.22 million during the quarter, compared to analyst estimates of $31.96 million. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%. As a group, sell-side analysts forecast that Zevra Therapeutics, Inc. will post 0.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ZVRA. Wall Street Zen cut Zevra Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday. Guggenheim upped their price target on Zevra Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, May 8th. BTIG Research began coverage on Zevra Therapeutics in a research report on Monday, March 16th. They set a “buy” rating and a $23.00 price target on the stock. Finally, Weiss Ratings cut Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research report on Friday, May 22nd. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $23.33.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.